Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003
Efficacy of standard chemotherapy regimen in patients with newly detected sputum-positive destructive pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment Source: International Congress 2017 – MDRTB: detection and management Year: 2017
Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Directly observed therapy versus self administered therapy for patients of new smear positive pulmonary tuberculosis during hospitalisation period Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Retreatment of tuberculosis patients after the treatment interruption Source: Eur Respir J 2006; 28: Suppl. 50, 506s Year: 2006
Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban Year: 2008
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
The clinical value of intravenous pulse therapy in first retreatment pulmonary tuberculosis patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Glucocorticosteroid treatment in sarcoidosis: comparison of regimens Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003
Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection Year: 2019
Efficacy of different preoperational treatment in patients with destructive pulmonary TB Source: Eur Respir J 2005; 26: Suppl. 49, 688s Year: 2005
Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021